TRK Fusion Cancer Study
Protocol: SITE00000072
Full Title
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
Description
This study enrolls people with TRK fusion cancer. The purpose of this study is to learn more about the effectiveness of the drug VITRAKVI (generic name: larotrectinib) for TRK fusion cancer that has spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion.

This is an observational study, which means you will continue with the treatment your doctor has recommended and we will collect some data about your health while you are in treatment and afterwards for about 2-5 years. You will have phone calls with the study team once in a while to help us learn how you have been doing medically. Study takes place at Kaleida Health facilities.

Technical Description

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months. Site For ON-TRK larotrectinib
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
Adults 18+
Patients with TRK fusion cancer (locally advanced or metastatic solid tumor harboring an NTRK gene fusion).
Your physician has decided to treat you with larotrectinib.
Age Group: Both Adults and Children
Principal Investigator: Basem Goueli
ClinicalTrials.gov: Open Study
Contact(s)
Deonna Coleman
dc84@buffalo.edu
Want to Learn More?
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.